The Prevalence and Incidence of Suicidal Thoughts and Behavior in a Smartphone-Delivered Treatment Trial for Body Dysmorphic Disorder: Cohort Study

Background: People with past suicidal thoughts and behavior (STB) are often excluded from digital mental health intervention (DMHI) treatment trials. This may perpetuate barriers to care and reduce treatment generalizability, especially in populations with elevated rates of STB, such as body dysmorphic disorder (BDD). We conducted a cohort study of randomized controlled trial (RCT) participants (N=80) who received a smartphone-based cognitive behavioral therapy (CBT) treatment for BDD that allowed for most forms of past STB, except for past-month active suicidal ideation. Objective: This study had two objectives: (1) to characterize the sample's lifetime prevalence of STB and (2) to estimate and predict STB incidence during the trial. Methods: We completed secondary analyses on data from an RCT of smartphone-delivered CBT for BDD. The primary outcomes consisted of STB severity and suicide attempt assessed at baseline with the Columbia-Suicide Severity Rating Scale (C-SSRS) and weekly during the trial via one item from the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR item #12; 1043 observations). We computed descriptive statistics (n, %) and ran a series of bi- and multivariate linear regressions predicting STB incidence during the 3-month trial. Results: At baseline, 40% of participants reported a lifetime history of active suicidal thoughts and 10% reported lifetime suicide attempts. During the 3-month trial, 42.5% reporting thinking about death or suicide via weekly assessment. No participants reported frequent or acute suicidal thoughts, plans, or attempts. Lifetime suicide attempt (odds ratio 11, 95% CI 2.14-59.14; P<.01) and lifetime severity of suicidal thoughts (odds ratio 1.76, 95% CI 1.21-2.77; P<.01) were significant bivariate predictors of death- or suicide-related thought incidence reported during the trial. Multivariate models including STB risk factor covariates (eg, age, and sexual orientation) modestly improved prediction of death or suicide-related thoughts (eg, positive predictive value=0.91, negative predictive value=0.75, and area under the receiver operating characteristic curve=0.83). Conclusions: Although some participants may think about death and suicide during a DMHI trial, it may be safe and feasible to include participants with most forms of past STB. Among other procedures, researchers should carefully select eligibility criteria, use frequent, ongoing, low-burden, and valid monitoring procedures, and implement risk mitigation protocols tailored to the presenting problem. Trial Registration: ClinicalTrials.gov NCT04034693; https://www.clinicaltrials.gov/study/NCT04034693